Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Declines By 21.2%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 13,400 shares, a drop of 21.2% from the October 15th total of 17,000 shares. Based on an average trading volume of 43,500 shares, the short-interest ratio is presently 0.3 days.

Global X Genomics & Biotechnology ETF Stock Down 3.9 %

Global X Genomics & Biotechnology ETF stock traded down $0.40 during midday trading on Friday, reaching $9.80. The company’s stock had a trading volume of 45,216 shares, compared to its average volume of 56,965. Global X Genomics & Biotechnology ETF has a fifty-two week low of $9.57 and a fifty-two week high of $12.53. The company has a market cap of $71.64 million, a P/E ratio of -4.36 and a beta of 1.03. The business has a 50-day simple moving average of $10.89 and a 200-day simple moving average of $10.86.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds have recently made changes to their positions in the company. Atria Investments Inc purchased a new stake in Global X Genomics & Biotechnology ETF in the 3rd quarter valued at approximately $122,000. Centaurus Financial Inc. acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the 2nd quarter valued at approximately $146,000. James J. Burns & Company LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the 2nd quarter valued at approximately $181,000. Rockefeller Capital Management L.P. acquired a new stake in shares of Global X Genomics & Biotechnology ETF during the 3rd quarter valued at approximately $205,000. Finally, Insight Advisors LLC PA lifted its position in shares of Global X Genomics & Biotechnology ETF by 59.0% during the 2nd quarter. Insight Advisors LLC PA now owns 21,177 shares of the company’s stock valued at $221,000 after acquiring an additional 7,861 shares during the period. Hedge funds and other institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.